Australia markets closed
  • ALL ORDS

    7,557.80
    -29.60 (-0.39%)
     
  • AUD/USD

    0.7162
    +0.0029 (+0.41%)
     
  • ASX 200

    7,235.90
    -20.10 (-0.28%)
     
  • OIL

    69.15
    +2.97 (+4.49%)
     
  • GOLD

    1,788.10
    +11.60 (+0.65%)
     
  • BTC-AUD

    79,687.07
    -651.09 (-0.81%)
     
  • CMC Crypto 200

    1,470.48
    +27.71 (+1.92%)
     

Bluechiip Limited (BCT.AX) Open Briefing Interview with Andrew McLellan

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Bluechiip Limited
Bluechiip Limited

Bluechiip Limited (BCT.AX) Open Briefing Interview with Andrew McLellan

Melbourne, Australia, Oct 28, 2021 - (ABN Newswire) - In this Open Briefing(R) interview, Bluechiip Limited (ASX:BCT) (HAM:1BL) MD Andrew McLellan discusses the September quarter 4C, License and Development agreement with US-based Fujifilm Irvine Scientific and the first sales of Bluechiip's own consumables.

To read the Open Briefing Interview, please visit:
https://abnnewswire.net/lnk/APYV068G


About Bluechiip Limited:


Bluechiip Limited (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Contact:

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au

Source:
Bluechiip Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting